1E Therapeutics (1Etx) is a breakthrough, clinical stage drug development company creating first-in-class RNA-targeting therapeutics based on our proprietary drug design platform. 1E is the culmination of years of innovation, effort, and tens of millions of $US investment in research and development.
1E's proprietary and groundbreaking rapid drug design process has proven uniquely able to develop innovative drugs that address chronic life threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology and age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders. 1E’s most advanced lead is already in a Phase 1/2 clinical trial, and the company is positioned to have multiple programs in the clinic within the next 2 years.